Details of the Drug Reposition

General Information of This Drug (ID: DM2HG4X)

Drug Name
Prednisone   DM2HG4X
Synonyms
Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
29 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Serum sickness DIS0MRKJ N.A. Approved [1]
Rheumatic heart disease DISCI8JQ N.A. Approved [1]
Prostate adenocarcinoma DISBZYU8 N.A. Approved [1]
Primary cutaneous T-cell lymphoma DIS35WVW N.A. Approved [1]
Polymyalgia rheumatica DIS5F36E N.A. Approved [1]
Erythema multiforme DISKCLM1 N.A. Approved [1]
Epicondylitis DIS0R2VM N.A. Approved [1]
Diamond-Blackfan anemia DISI2SNW N.A. Approved [1]
Childhood acute lymphoblastic leukemia DISJ5D6U N.A. Approved [1]
Inflammation DISJUQ5T 1A00-CA43.1 Approved [1]
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Approved [2]
Small lymphocytic lymphoma DIS30POX 2A82.0 Approved [1]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Mycosis fungoides DIS62RB8 2B01 Approved [1]
Autoimmune haemolytic anaemia DIS7MS3M 3A20 Approved [1]
Angioedema DIS90QDN 4A00.15 Approved [1]
Systemic lupus erythematosus DISI1SZ7 4A40.0 Approved [1]
Sarcoidosis DISE5B8Z 4B20.5 Approved [1]
Congenital adrenal hyperplasia DISG873W 5A71.01 Approved [1]
Addison disease DIS7HNOH 5A74.0 Approved [1]
Multiple sclerosis DISB2WZI 8A40 Approved [1]
Allergic rhinitis DIS3U9HN CA08.0 Approved [1]
Acute asthma DISGYB62 CA23 Approved [1]
Crohn disease DIS2C5Q8 DD70 Approved [1]
Inflammatory bowel disease DISGN23E DD72 Approved [1]
Skin disease DISDW8R6 EA00-EM0Z Approved [1]
Psoriasis DIS59VMN EA90 Approved [1]
Dermatitis herpetiformis DIS0TC0G EB44 Approved [1]
Psoriatic arthritis DISLWTG2 FA21 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 Indications(s)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Atopic dermatitis DISTCP41 EA80 Phase 1 [3]
Eczema DIS3N7H0 EA80-EA89 Phase 1 [3]
------------------------------------------------------------------------------------
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pemphigus DISZAZ6M N.A. Withdrawn [4]
------------------------------------------------------------------------------------
3 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Nephrotic syndrome DISSPSC2 N.A. Discontinued in Phase 3 [5]
Thyroiditis DISTCV24 N.A. Discontinued in Phase 3 [6]
Ankylosing spondylitis DISRC6IR FA92.0 Discontinued in Phase 3 [7]
------------------------------------------------------------------------------------
4 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute lymphocytic leukaemia DISPX75S 2B33.3 Discontinued in Phase 2 [8]
Autoimmune disease DISORMTM 4A40-4A45 Discontinued in Phase 2 [9]
Musculoskeletal disorder DISPPN0O FA00-FC0Z Discontinued in Phase 2 [10]
Arthritis DIST1YEL FA20 Discontinued in Phase 2 [11]
------------------------------------------------------------------------------------
5 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Humoral hypercalcemia of malignancy DISQQ62D N.A. Discontinued in Phase 1 [12]
Exfoliative dermatitis DISQEWIW N.A. Discontinued in Phase 1 [13]
Malaria DISQ9Y50 1F40-1F45 Discontinued in Phase 1 [14]
Diffuse large B-cell lymphoma DISSACK3 2A81 Discontinued in Phase 1 [15]
Contact dermatitis DISQ3AU0 EK0Z Discontinued in Phase 1 [16]
------------------------------------------------------------------------------------
5 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Trichinellosis DISUR2ZW N.A. Investigative [1]
Classic Hodgkin lymphoma DISV1LU6 N.A. Investigative [1]
Beta-thalassemia major DISW06BV N.A. Investigative [1]
Acquired thrombocytopenia DISXH01C N.A. Investigative [1]
Follicular lymphoma DISVEUR6 2A80 Investigative [1]
------------------------------------------------------------------------------------

References

1 Prednisone FDA Label
2 Certain corticosteroid could improve severe COVID-19, say researchers. May 20, 2020
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Inflammation Control For Elders: ICE Study
5 Caries Transmission Prevention in Alaska Native Infants
6 Everolimus on CKD Progression in ADPKD Patients
7 An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
8 A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
9 Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
10 Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
11 Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
12 Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
13 Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
14 Safety Study of Latanoprost Slow Release Insert
15 Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
16 Insulin and Sarcopenia in the Elderly